Correction: Inhibition of astrocyte signaling leads to sex-specific changes in microglia phenotypes in a diet-based model of cerebral small vessel disease (Journal of Neuroinflammation, (2025), 22, 1, (202), 10.1186/s12974-025-03523-2)

In this article [1], the wrong figure appeared as Fig. 5; the figure 5 should have appeared as shown below. The original article has been corrected. Differentially expressed microglial genes and KEGG pathway mapping in males. A, Volcano plot shows microglial DEGs that are upregulated (HHcy Up, red) and downregulated (HHcy Down, blue) in the HHcy-EGFP vs CT EGFP treatment conditions. B, KEGG pathways enriched for HHcy-sensitive (upregulated) DEGs. C, Volcano plot shows microglial DEGs that are upregulated (VIVIT Up, red) and downregulated (VIVIT Down, blue) by VIVIT in the CT-EGFP vs CT VIVIT treatment conditions. D, KEGG pathways enriched for VIVIT-sensitive (downregulated) DEGs in the CT EGFP vs CT VIVIT conditions. E, Volcano plot shows microglial DEGs that are upregulated (VIVIT Up, red) and downregulated (VIVIT Down, blue) by VIVIT in the HHcy-EGFP vs HHcy VIVIT treatment conditions. F, KEGG pathways enriched for VIVIT-sensitive (downregulated) DEGs in the HHcy EGFP vs HHcy VIVIT conditions. G, Venn diagrams showing DEGs that are sensitive to both HHcy (872 genes upregulated in HHcy EGFP vs CT EGFP comparison) and VIVIT (2233 genes downregulated in HHcy VIVIT vs HHcy EGFP). More than 90% of the HHcy sensitive genes (773 genes) were also sensitive to VIVIT treatment. The statistical significance of the overlap was assessed using Fisher’s exact test implemented via the GeneOverlap R package. The observed overlap of 773 genes is significantly enriched (p < 8.5 × 10^–142; odds ratio = 10.27). For all measures, data were pooled from two replicates (two mice) per treatment group.